-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 10, Sanofi and Sobi jointly announced a pivotal Phase 3 clinical trial of their co-developed long-acting hemophilia A therapy efanesoctocog alfa (BIVV001) in patients over 12 years of age with severe hemophilia A positive top-line results
Hemophilia A is a genetic disorder in which FVIII is missing due to mutations in the gene encoding FVIII
The half-life of native FVIII in the blood is only about 12 hours, because in the blood it binds to von Willebrand factor (VWF) to form a complex
The design of BIVV001 links FVIII to a VWF fragment, and the resulting complex does not bind to native VWF in the blood, thus breaking the upper half-life limit set by VWF
▲Schematic diagram of the structure of BIVV001 (Image source: Reference [2])
This open-label, non-randomized Phase 3 clinical trial was conducted in 159 patients over 12 years of age with severe hemophilia
References:
[1] Efanesoctocog alfa met primary and key secondary endpoints in pivotal study in hemophilia A, demonstrating superiority to prior factor prophylaxis treatment.
[2] Konkle et al.
(Original abridged)
